S. Herschorn, J. Nazir, B. Ramos, and Z. Hakimi, “Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada”, CUAJ, vol. 11, no. 3-4, pp. 123–30, Apr. 2017.